Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.86 USD
-0.06 (-6.20%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.86 0.00 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ONCY 0.86 -0.06(-6.20%)
Will ONCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCY
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ONCY Stock Up on Regulatory Update From Breast Cancer Program
Other News for ONCY
Oncolytics Biotech GAAP EPS of -$0.07
Oncolytics reports Q2 EPS (C$0.07) vs. (C$0.10) last year
Oncolytics voluntarily delists common shares from Toronto Stock Exchange